Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
Salt Lake City
Archived
•
May 19, 2026
•
2 views
SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that its Phase 3 clinical data for LPCN 1154 have been…
Source: https://www.tremontonleader.com/search/?f=rss&t=article&l=50&c=news* - Read Original
"5000+ Emails weekly."
"Retirement Health Care"
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!
Sponsored
"Water and Showers while camping is so simple."
"Because adventure is exploring the unknown"